CLAUDIA UKPOLO: Open Payments
NPI 1811303829 · NEW ORLEANS, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$329 in 12 payments from 9 companies in 2025. Trend: 2023 $703 · 2024 $512 · 2025 $329
Food & beverage: $329
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 3 | $83 |
| Collegium Pharmaceutical, Inc. | 1 | $63 |
| Supernus Pharmaceuticals, Inc. | 1 | $45 |
| ABBVIE INC. | 2 | $43 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Indivior Inc. | 1 | $15 |
Products named: INGREZZA, Jornay PM, Qelbree, VRAYLAR, Auvelity, CAPLYTA, UZEDY, ONZETRA XSAIL.
Industry payments across LA — which companies pay providers there.
